by Richard Daverman, PhD
August 23, 2012 -- Hangzhou Tigermed Consulting, a China CRO, signed a letter of intent with MSD China that calls for Tigermed to provide MSD with clinical trial services for a three-year period, from August 15, 2012 to July 31, 2015. Neither the range of services, the type of drug(s) involved, nor the financial details of the relationship were disclosed, probably awaiting a closing agreement. MSD is the name for Merck outside of the US and Canada. More details....
Stock Symbols: (SHE: 300347) (NYSE: MRK)
